This is early beta for now! Can't handle all templates properly
Hankkija
| Vastaanotettu Hilmaan | 2022-08-16 |
| Ilmoituksen numero | 2022-106533 |
| TED numero | 2022/S 159-453218 |
| Ostajaorganisaatio | Ministry of Social Affairs and Health (0244685-8 ) P.O. BOX 33 FI-00023 Helsinki https://stm.fi/en/frontpage |
| Hankinnan otsikkotiedot | Measles, Mumps, Rubella (MMR) Vaccine 2023-2025 (2025-2026, 2026-2027) |
| Hankinnan yhteenlaskettu kokonaisarvo koko ajalle (ilman alv:ta) arvio | |
| Hankinnan yhteenlaskettu kokonaisarvo koko ajalle (ilman alv:ta) lopullinen | 2 547 600 EUR |
| Alkuperäinen ilmoitus | https://www.hankintailmoitukset.fi/en/public/procurement/60621/notice/106533/overview |
| Originaali JSON tietue | 106533.json |
Ostettava
| Hankinnan lyhyt kuvaus | The purpose of STM and the Customer is to procure Measles, Mumps, Rubella (MMR) Vaccine required for the National Vaccination Programme in Finland. The tendered vaccine must be suitable for children, adolescents and adults. More information about National Vaccination Programme and vaccinations can be found on the website of the National Institute for Health and Welfare https://thl.fi/en/web/infectious-diseases-and-vaccinations/vaccines-a-to-z/mmr-or-measles-mumps-and-rubella-vaccine The Customer will implement the procurement on behalf of STM. The roles of STM and Customer are described in more detail in section "Presentation of the contracting authority". |
| Hankintanimikkeistö (CPV) pää | Vaccines (33651600) |
| Hankintanimikkeistö (CPV) muut | |
| Aluekoodi | FI |
| Pääasiallinen suorituspaikka |
Sopimukset
| Päätös päivämäärä | 2022-06-29 |
| Sopimusnumero | 1 |
| Myyjät | GlaxoSmithKline Oy (FI), 0108378-4 |
